

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and managing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-331/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-331" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and managing cutaneous T-cell lymphomas" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and managing cutaneous T-cell lymphomas.">
            <meta name="og:description" content="Read the latest article version by Patrick M. Brunner, Constanze Jonak, Robert Knobler, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24172">
            <meta name="article-id" content="21922">
            <meta name="dc.title" content="Recent advances in understanding and managing cutaneous T-cell lymphomas">
            <meta name="dc.description" content="Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients&rsquo; health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics.">
            <meta name="dc.subject" content="Cutaneous T cell lymphoma, Mycosis fungoides, S&eacute;zary Syndrome, health-related quality of life, tissue resident memory T cells">
            <meta name="dc.creator" content="Brunner, Patrick M.">
            <meta name="dc.creator" content="Jonak, Constanze">
            <meta name="dc.creator" content="Knobler, Robert">
            <meta name="dc.date" content="2020/05/05">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.21922.1">
            <meta name="dc.source" content="F1000Research 2020 9:331">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Cutaneous T cell lymphoma">
            <meta name="prism.keyword" content="Mycosis fungoides">
            <meta name="prism.keyword" content="S&eacute;zary Syndrome">
            <meta name="prism.keyword" content="health-related quality of life">
            <meta name="prism.keyword" content="tissue resident memory T cells">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/05/05">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="331">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.21922.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-331">
            <meta name="citation_title" content="Recent advances in understanding and managing cutaneous T-cell lymphomas">
            <meta name="citation_abstract" content="Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients&rsquo; health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics.">
            <meta name="citation_description" content="Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients&rsquo; health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics.">
            <meta name="citation_keywords" content="Cutaneous T cell lymphoma, Mycosis fungoides, S&eacute;zary Syndrome, health-related quality of life, tissue resident memory T cells">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Patrick M. Brunner">
            <meta name="citation_author_institution" content="Department of Dermatology, Medical University of Vienna, W&auml;hringer G&uuml;rtel 18-20, Vienna, 1090, Austria">
            <meta name="citation_author" content="Constanze Jonak">
            <meta name="citation_author_institution" content="Department of Dermatology, Medical University of Vienna, W&auml;hringer G&uuml;rtel 18-20, Vienna, 1090, Austria">
            <meta name="citation_author" content="Robert Knobler">
            <meta name="citation_author_institution" content="Department of Dermatology, Medical University of Vienna, W&auml;hringer G&uuml;rtel 18-20, Vienna, 1090, Austria">
            <meta name="citation_publication_date" content="2020/05/05">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="331">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.21922.1">
            <meta name="citation_firstpage" content="331">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-331/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-331.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24172 /> <input type=hidden id=articleId name=articleId value=21922 /> <input type=hidden id=xmlUrl value="/articles/9-331/v1/xml"/> <input type=hidden id=xmlFileName value="-9-331-v1.xml"> <input type=hidden id=article_uuid value=e6ec8946-a656-4e78-9c94-15b791da32af /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and managing cutaneous T-cell lymphomas"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.21922.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.21922.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-331"
  },
  "headline": "Recent advances in understanding and managing cutaneous T-cell lymphomas",
  "datePublished": "2020-05-05T15:26:36",
  "dateModified": "2020-05-05T15:26:36",
  "author": [
    {
      "@type": "Person",
      "name": "Patrick M. Brunner"
    },    {
      "@type": "Person",
      "name": "Constanze Jonak"
    },    {
      "@type": "Person",
      "name": "Robert Knobler"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients&rsquo; health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-331",
            "name": "Recent advances in understanding and managing cutaneous T-cell lymphomas"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and managing cutaneous T-cell lymphomas </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24172 data-id=21922 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21922.1" data-recommended="" data-doi="10.12688/f1000research.21922.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-331/v1/pdf?article_uuid=e6ec8946-a656-4e78-9c94-15b791da32af" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-21922-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-21922-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-21922-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Brunner PM, Jonak C and Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):331 (<a class=new-orange href="https://doi.org/10.12688/f1000research.21922.1" target=_blank>https://doi.org/10.12688/f1000research.21922.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-21922-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=21922 id=track-article-signin-21922 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21922?target=/articles/9-331">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24172 /> <input name=articleId type=hidden value=21922 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and managing cutaneous T-cell lymphomas</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Patrick M. Brunner<a href="https://orcid.org/0000-0002-3488-3345" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3488-3345</div>,&nbsp;</span><span class="">Constanze Jonak,&nbsp;</span><span class=""><a href="mailto:robert.knobler@meduniwien.ac.at" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Robert Knobler</span></a><a href="https://orcid.org/0000-0002-7380-7062" target=_blank id=author-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7380-7062</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Patrick M. Brunner<a href="http://orcid.org/0000-0002-3488-3345" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3488-3345</div>,&nbsp;</span><span class="">Constanze Jonak,&nbsp;</span><span class=""><a href="mailto:robert.knobler@meduniwien.ac.at" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Robert Knobler</span></a><a href="http://orcid.org/0000-0002-7380-7062" target=_blank id=mauthor-orcid-2><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-2><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-7380-7062</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 05 May 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.21922.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Dermatology, Medical University of Vienna, W&auml;hringer G&uuml;rtel 18-20, Vienna, 1090, Austria<br/> <p> <div class=margin-bottom> Patrick M. Brunner <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Constanze Jonak <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Robert Knobler <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=67016-62929></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=67015-62930></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Cutaneous T-cell lymphomas (CTCLs) comprise a heterogeneous group of extranodal non-Hodgkin lymphomas involving primarily the skin and mycosis fungoides is its most frequent entity. Whereas most patients show an indolent course in early disease (clinical stages IA to IIA), some patients progress to advanced disease (stage IIB or higher), and the 5-year survival rate is unfavorable: only 47% (stage IIB) to 18% (stage IVB). Except for allogeneic stem cell transplantation, there is currently no cure for CTCL and thus treatment approaches are palliative, focusing on patients’ health-related quality of life. Our aims were to review the current understanding of the pathogenesis of CTCL, such as the shift in overall immune skewing with progressive disease and the challenges of making a timely diagnosis in early-stage disease because of the lack of reliable positive markers for routine diagnostics, and to discuss established and potential treatment modalities such as immunotherapy and novel targeted therapeutics. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Cutaneous T cell lymphoma, Mycosis fungoides, Sézary Syndrome, health-related quality of life, tissue resident memory T cells </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Robert Knobler (<a href="mailto:robert.knobler@meduniwien.ac.at">robert.knobler@meduniwien.ac.at</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Robert Knobler </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> PMB is an employee of the Medical University of Vienna; has received personal fees from LEO Pharma, Pfizer, Sanofi, Eli Lilly and Company, Novartis, Celgene, UCB Pharma, Biotest, Boehringer Ingelheim, AbbVie, Amgen, and Arena Pharmaceuticals; is an investigator for Novartis (grant paid to his institution); and has received a grant from Celgene (paid to his institution). CJ is an employee of the Medical University of Vienna; has received personal fees from LEO Pharma, Pfizer, Eli Lilly and Company, Novartis, Takeda, Mallinckrodt/Therakos, AbbVie, Janssen, and Almirall; and is an investigator for Eli Lilly and Company, Novartis, and 4SC (grant paid to her institution). RK is an employee of the Medical University of Vienna and has received personal fees from Mallinckrodt/Therakos. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Brunner PM <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Brunner PM, Jonak C and Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):331 (<a href="https://doi.org/10.12688/f1000research.21922.1" target=_blank>https://doi.org/10.12688/f1000research.21922.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 05 May 2020, <b>9</b>(F1000 Faculty Rev):331 (<a href="https://doi.org/10.12688/f1000research.21922.1" target=_blank>https://doi.org/10.12688/f1000research.21922.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 05 May 2020, <b>9</b>(F1000 Faculty Rev):331 (<a href="https://doi.org/10.12688/f1000research.21922.1" target=_blank>https://doi.org/10.12688/f1000research.21922.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d1044e157>Introduction</h2><p class="" id=d1044e160>Cutaneous T-cell lymphomas (CTCLs) are primary lymphomas of the skin, and the estimated incidence is about 5.6 per million<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The term CTCL comprises a group of malignancies that develop from skin-homing T cells, which are of the CD4<sup>+</sup> T helper cell type in more than 90% of cases<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The most frequent clinical entity of CTCL is mycosis fungoides (MF), accounting for about 60% of all cases, followed by primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders and much rarer entities such as Sézary syndrome (SS). The 2018 update of the World Health Organization–European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for cutaneous lymphomas describes new provisional entities—namely chronic active Epstein–Barr virus infection, CD8<sup>+</sup> aggressive epidermotropic CTCL, primary cutaneous CD4<sup>+</sup> small/medium T-cell lymphoproliferative disorder, and primary acral CD8<sup>+</sup> T-cell lymphoma—which are now included<sup><a href="#ref-3">3</a></sup>. In early disease stages, MF presents clinically with erythematous patches or plaques and this stage can last for many years without clinical progression and without affecting the life expectancy of the patient<sup><a href="#ref-4">4</a></sup>. Nevertheless, CTCLs may be disfiguring and thus have an impact on patients’ health-related quality of life (HRQoL)<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. In about 30% of patients presenting with early-stage CTCL, the disease progresses to advanced-stage disease within 10 years<sup><a href="#ref-7">7</a></sup> by gradually developing into tumors and may disseminate to lymph nodes, blood, and internal organs, resulting in an unfavorable prognosis<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>; 5-year overall survival rates decrease from 94% in stage IA to as low as 18% in stage IVB<sup><a href="#ref-10">10</a></sup>. However, in rare cases, MF can also initially present with tumors representing the disease variant “tumour d’emblée”. It is still unclear why about 30% of patients with CTCL<sup><a href="#ref-7">7</a></sup> progress to advanced disease; currently, prediction of prognosis is based predominantly on clinical staging by using the TNMB (tumor, node, metastasis, blood) classification for MF/SS<sup><a href="#ref-11">11</a></sup> and there are additional roles for gender, age, blood lactate dehydrogenase concentration, folliculotropism, large-cell transformation, and the detection of clonality<sup><a href="#ref-10">10</a></sup>. Of note, no validated biomarkers, favorable or unfavorable, are available for the prediction of the disease course<sup><a href="#ref-12">12</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1044e243>Disease etiology and pathogenesis</h2><p class="" id=d1044e246>The etiology of most variants of CTCL remains only poorly understood. Potential etiologic factors include infectious agents, ultraviolet (UV) light, or occupational exposures<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Large-scale mutational genome profiling analyses identified genomic alterations in several putative oncogenes and tumor suppressor genes, including <i>CARD11</i>, <i>CCR4, TP53, NF-κB</i>, and Janus kinase signaling members<sup><a href="#ref-15">15</a>–<a href="#ref-19">19</a></sup>, but heterogeneity between individual patients can be considerable<sup><a href="#ref-15">15</a>–<a href="#ref-19">19</a></sup>. It is assumed that, besides a dysfunctional regulation of cytokines and other signaling molecules that most likely play a decisive role for malignant transformation, epigenetic modifications such as pathologic gene methylation and histone deacetylation play a role in malignant transformation of CTCL cells<sup><a href="#ref-20">20</a></sup>.</p><p class="" id=d1044e281>In MF, the malignant T cells have been identified as typically CD4<sup>+</sup> skin-resident effector memory T cells of clonal origin<sup><a href="#ref-21">21</a></sup>. Their skin-resident nature explains why MF lesions tend to be primarily present in the skin in most patients<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. By contrast, SS cells are classified as of the central memory phenotype (expressing the lymph node homing molecules CCR7 and L-selectin), enabling these cells to freely move from the periphery to lymphoid organs<sup><a href="#ref-21">21</a>,<a href="#ref-22">22</a></sup>. Consistently, the phenotype of SS typically shows erythroderma as well as blood and lymph node involvement.</p><p class="" id=d1044e305>CTCL cells have been described to express cytokines of various helper cell subtypes, including T helper 2 (Th2), Th17, and regulatory T cells<sup><a href="#ref-23">23</a>–<a href="#ref-25">25</a></sup>. In addition, many other chemokines and cytokines are being produced within lesions, adding to the overall complexity of the disease<sup><a href="#ref-26">26</a></sup>. Histologically, malignant T cells are characterized by epidermotropism—that is, they are preferentially present in the upper parts of the skin (epidermis)—whereas non-malignant T cells are detected primarily in the dermis, especially in early MF. This early immune infiltrate consists primarily of non-malignant Th1 cells, regulatory T cells, and cytotoxic CD8<sup>+</sup> T cells (tumor-infiltrating lymphocytes, or TILs), which are hypothesized to (initially) keep the malignant T cells under control<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>, but the precise mechanisms remain unclear. During progression of the disease, a switch from the benign “bystander” infiltrate of Th1 cells and CD8<sup>+</sup> TILs to a more Th2-biased phenotype, including the appearance of blood eosinophilia and markedly elevated IgE blood levels<sup><a href="#ref-26">26</a></sup>, has been documented<sup><a href="#ref-29">29</a></sup>. Conversely, therapeutic success in MF during skin-directed psoralen plus UVA (PUVA) therapy was linked to a shift from Th2 toward a Th1 phenotype with clearance of the skin lesions irrespective of tumor cell burden, implicating an increased turnover of benign T cells<sup><a href="#ref-30">30</a></sup>. Thus, Th1 immune skewing in early-stage disease is traditionally considered protective (produced by the accompanying “anti-tumor” infiltrate), whereas a gradual loss of this Th1 signature, with an increase in Th2 mediators, is regarded as a sign of disease progression<sup><a href="#ref-31">31</a></sup>. It is assumed that, mechanistically, tumor-derived Th2 cytokines suppress proliferation of benign T cells and inhibit dendritic cell (DC) maturation<sup><a href="#ref-32">32</a></sup>. Such a Th2-dominant skin immune skewing is also found in atopic dermatitis; intriguingly, both patients with MF and those with atopic dermatitis have <i>Staphylococcus aureus</i> colonization and increased rates of infectious complications<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Recent data even suggest that staphylococcal alpha toxin itself may promote disease progression through positive selection of CD4<sup>+</sup> tumor cells<sup><a href="#ref-35">35</a></sup>. In line with its opposing effect toward Th2-associated inflammation, the major Th1 cytokine interferon-gamma (IFN-γ) shows some efficacy in CTCL treatment<sup><a href="#ref-36">36</a></sup>. However, other cells, including fibroblasts, keratinocytes, and endothelial cells, are thought to promote and augment a Th2 microenvironment in advanced-stage MF, thereby further attenuating Th1 immune responses<sup><a href="#ref-37">37</a></sup>.</p><p class="" id=d1044e379>DCs have the unique capacity to induce primary immune responses by activating naïve T cells and thus are the central gatekeepers for the initiation of adaptive immune responses<sup><a href="#ref-38">38</a></sup>. As recently shown, c-Kit<sup>+</sup>OX40L<sup>+</sup>CD40L<sup>+</sup> DCs can foster the visible skin inflammation within skin lesions by recruiting and activating benign T cells and this mechanism likely provides key tumorigenic signals within the CTCL immune microenvironment<sup><a href="#ref-30">30</a></sup>. In advanced-stage CTCL, the maturation of DCs is thought to be suppressed by Th2 cytokines<sup><a href="#ref-32">32</a></sup>. Importantly, immature DCs can induce tolerance by presenting antigens to T cells without appropriate co-stimulation, thus fostering a tumor-tolerating (micro)environment rather than an anti-tumor immune defense<sup><a href="#ref-39">39</a></sup>. Consistently, increased levels of immature DCs are found in MF lesions, which might be an important mechanism for tolerance against malignant T cells<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d1044e413>Keratinocytes produce multiple chemokines, including CCL17, CCL26, CCL27, CXCL9, and CXCL10, which are potent chemo-attractants for several immune cell populations. They also produce nerve growth factor, which is suggested to be involved in itch development, a typical symptom for CTCL<sup><a href="#ref-26">26</a></sup>. Mast cells might also be involved in CTCL pathogenesis, as their number correlates with disease progression<sup><a href="#ref-41">41</a></sup>. Similarly, myeloid-derived suppressor cells increase with advanced disease stage<sup><a href="#ref-42">42</a></sup>, and immunosuppressive M2 macrophages are known to promote tumor growth in various cancers<sup><a href="#ref-43">43</a></sup> and could also play a role in CTCL<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup>. Overall, there is a complex interplay between tumor cells and the tissue microenvironment, which is not yet fully elucidated.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1044e442>Diagnosis of disease</h2><p class="" id=d1044e445>In CTCL, genetic markers are currently under intense investigation as potential diagnostic tools, but single diagnostic biomarkers are still lacking. Thus, the integration of clinical morphology, histology, immune-phenotype, and molecular biological data remains essential for an accurate diagnosis<sup><a href="#ref-3">3</a></sup>. Accordingly, the diagnosis of CTCL is based on the combination and correlation of the three following assessments: (a) clinical observations, (b) (immuno)histological examination of skin biopsies, and (c) additional laboratory tests such as flow cytometry of peripheral blood and the analysis of T-cell receptor (TCR) clonality by polymerase chain reaction (PCR)<sup><a href="#ref-47">47</a></sup>. The parameter of large-cell transformation of MF cells, based on histological criteria, is found in 56 to 67% of patients with advanced-stage MF<sup><a href="#ref-9">9</a></sup> and linked to an aggressive disease course with shortened survival. Besides malignant T cells, an abundant number of reactive immune cells, including high numbers of non-malignant T cells, accompany the malignant clone. Molecular and immunohistochemistry markers that are currently used to diagnose MF are usually negative markers, such as loss of expression of, for example, CD7 or CD26, but this kind of aberrant surface expression shows considerable variability from case to case<sup><a href="#ref-48">48</a></sup>. Useful positive diagnostic markers are still lacking for routine diagnostics. Importantly, the actual lymphoma cells are present in only small numbers during early stages of the disease. Thus, analyses of clonality (TCR rearrangement) are often falsely negative in early MF<sup><a href="#ref-49">49</a></sup>. Rea <i>et al.</i> showed that, for CTCL diagnosis, high-throughput sequencing was more specific than <i>TCR gamma chain</i> gene PCR (100% versus 88%) but that sensitivity (68% versus 72%) and accuracy (84% versus 80%) were similar<sup><a href="#ref-50">50</a></sup>. Thus, high-throughput sequencing, assessing both clonality and T-cell fractions in skin biopsies, is a promising tool to increase diagnostic accuracy in CTCL<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d1044e483>TOX (thymocyte selection-associated high-mobility group box) has been found to be strongly upregulated in early MF compared with lower levels in benign inflammatory dermatitis<sup><a href="#ref-51">51</a></sup>. Although TOX has insufficient sensitivity and specificity to serve as a single diagnostic marker, it might have an adjunctive diagnostic role together with other clinical and histological data<sup><a href="#ref-52">52</a></sup>. For SS, CD27 might serve as a diagnostic tool to distinguish this disease from benign inflammatory erythroderma<sup><a href="#ref-53">53</a></sup>. Nevertheless, the overall lack of validated and specific diagnostic markers adds to the fact that, in MF, for instance, it takes a median of about 3 years<sup><a href="#ref-7">7</a></sup> from the initial appearance of skin lesions until a definitive diagnosis can be made, demonstrating the difficulty of making a timely diagnosis, which mandates further research.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1044e505>Current lack of prognostic biomarkers that can predict disease progression</h2><p class="" id=d1044e508>The prediction of disease progression and overall survival in patients with MF has turned out to be a challenging endeavor<sup><a href="#ref-54">54</a></sup>. A Cutaneous Lymphoma International Prognostic Index (CLIPI), which includes age, gender, folliculotropism, and TNMB staging, has been developed but has limited utility in early-stage patients<sup><a href="#ref-55">55</a>,<a href="#ref-56">56</a></sup>. The CXCR4–CXCL12 axis has been described as a potential player in MF progression<sup><a href="#ref-57">57</a></sup>, but other authors did not consistently find differences between early and late disease stages<sup><a href="#ref-58">58</a></sup>. Recently, however, De Masson <i>et al.</i> used high-throughput sequencing of the <i>TCR beta</i> gene and found that an increased frequency of the malignant T-cell clone in MF skin lesions is strongly correlated with reduced overall survival in patients with early-stage disease<sup><a href="#ref-55">55</a></sup>.</p><p class="" id=d1044e541>Several authors showed associations of poor disease outcome with <i>TOX</i><sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup> as well as <i>miR-155, miR-21</i>, and <i>let-7i</i> microRNA expression<sup><a href="#ref-17">17</a>,<a href="#ref-47">47</a></sup>. Lefrançois <i>et al.</i><sup><a href="#ref-54">54</a></sup> described <i>TOX</i>, <i>FYB, CCR4</i>, and <i>CD52</i> as markers for disease progression and decreased survival in MF, and the authors confirmed these markers in an independent cohort of patients with SS. KIR3DL2, a recently discovered marker of the malignant clonal cell population in SS, was suggested as an independent prognostic factor for SS-specific death<sup><a href="#ref-61">61</a></sup>. Nevertheless, none of these potential biomarkers has been fully validated so far<sup><a href="#ref-55">55</a>,<a href="#ref-62">62</a></sup> and thus they are not yet available for clinical use.</p><p class="" id=d1044e593>One major factor limiting our insight into MF/SS pathogenesis is likely rooted in the considerable disease heterogeneity seen between individual patients<sup><a href="#ref-63">63</a></sup>. Importantly, significant heterogeneity of gene expression was present not only between different patients but also within the same individual over time<sup><a href="#ref-12">12</a>,<a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. Importantly, all of these studies used bulk tissue investigations or conventional immunohistochemistry studies or both. However, bulk tissue investigations do not distinguish between individual cell types (for example, the actual tumor cell and the tumor microenvironment), and conventional measurements of cell heterogeneity such as immunohistochemistry can suffer from artifacts and are impractical when several markers are investigated at the same time<sup><a href="#ref-66">66</a></sup>. Single-cell RNA sequencing has been shown to be a powerful tool to characterize complex as well as rare immune cell populations and to reveal unexpected or undescribed cell subpopulations, allowing the acquisition of large amounts of transcriptional information for the accurate and unbiased molecular characterization of these rare cells<sup><a href="#ref-67">67</a></sup>. Gaydosik <i>et al.</i><sup><a href="#ref-63">63</a></sup> performed a first investigation in advanced-stage CTCL and healthy control samples using single-cell RNA sequencing and found large inter- and intra-tumor gene expression heterogeneity in the T lymphocyte subset. Borcherding <i>et al.</i><sup><a href="#ref-68">68</a></sup> investigated CTCL heterogeneity in circulating SS cells, giving insight into the heterogeneity of SS cells within a single patient and putting transcriptomic differences into context with published MF data. Though still at the beginning in CTCL, the evolution of single-cell transcriptomics might offer exciting new opportunities to better understand tumor cell heterogeneity and to facilitate the development of stratified diagnostic and prognostic approaches for patients with CTCL.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1044e634>Novel treatment approaches</h2><p class="" id=d1044e637>There is currently no cure for CTCL, except for allogeneic stem cell transplantation, which carries a significant risk of relapse as well as treatment-related toxicity and death<sup><a href="#ref-69">69</a></sup>. Immunotherapy including checkpoint inhibitors for CTCL is only at the beginning and might be a promising tool to achieve long-term disease control<sup><a href="#ref-70">70</a></sup>, but the results of ongoing clinical trials must be awaited before making firm conclusions. Currently, CTCL treatment is based on a stage-related therapeutic approach. Thus, early-stage disease is first treated with skin-directed therapies<sup><a href="#ref-2">2</a>,<a href="#ref-71">71</a></sup>. These include topical application of glucocorticosteroids, topical mechlorethamine<sup><a href="#ref-72">72</a></sup>, topical bexarotene, and the use of phototherapy (UVB and PUVA)<sup><a href="#ref-73">73</a></sup> or localized radiation therapy (photon or electron beam). In addition, early-phase clinical trials or case series (or both) suggest a potential role for topical Toll-like receptor (TLR) agonists such as imiquimod<sup><a href="#ref-74">74</a></sup> or resiquimod<sup><a href="#ref-75">75</a></sup>, photodynamic therapy<sup><a href="#ref-76">76</a></sup>, and excimer laser therapy<sup><a href="#ref-77">77</a></sup>, but data are limited and need corroboration in larger clinical trials. Interestingly, resiquimod showed regression not only of treated but also of untreated lesions in a phase 1 study<sup><a href="#ref-75">75</a></sup> and is being further investigated as a skin-directed compound.</p><p class="" id=d1044e684>Widespread, advanced disease or refractory early-disease requires systemic therapy. Established treatment modalities include low-dose methotrexate, systemic bexarotene, IFN, the histone deacetylase inhibitors romidepsin and vorinostat, the anti-CD52 antibody alemtuzumab<sup><a href="#ref-78">78</a></sup>, extracorporeal photopheresis, and single-agent or combination chemotherapy.</p><p class="" id=d1044e691>Mogamulizumab is a monoclonal antibody directed against the chemokine receptor CCR4 and has been investigated in a phase 3 trial in comparison with vorinostat in patients with previously treated CTCL<sup><a href="#ref-79">79</a></sup>. The investigators showed that mogamulizumab resulted in a median progression-free survival of 7.7 months, compared with only 3.1 with the active comparator, and an objective response rate of 28% versus 5%. Surprisingly, vorinostat response rates were actually lower than in initial studies<sup><a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>. Response rates to mogamulizumab were independent of previous therapies<sup><a href="#ref-82">82</a></sup>; long-term treatment seems to be safe and well tolerated<sup><a href="#ref-82">82</a></sup>. Thus, mogamulizumab might also be an option for heavily pre-treated patients, and besides MF, this agent seems to be particularly promising for patients with SS<sup><a href="#ref-79">79</a></sup>.</p><p class="" id=d1044e717>Brentuximab vedotin is an antibody–drug conjugate designed to target CD30 in CD30<sup>+</sup> CTCL<sup><a href="#ref-83">83</a></sup>. Although efficacy was reported to be better in CD30-expressing CTCL, clinical responses were still observed in patients with lower CD30 expression<sup><a href="#ref-82">82</a></sup>. Thus, this treatment might also be an option for a wider range of CTCLs beyond those highly expressing CD30.</p><p class="" id=d1044e732>Owing to the chronic-relapsing nature of CTCLs, there are also investigations into maintenance therapy using lower treatment doses or frequencies or both. There are some promising data on maintenance PUVA therapy extending median disease-free remission from 4 to 15 months<sup><a href="#ref-73">73</a></sup>. Resminostat is being investigated in a phase 2 clinical trial for maintenance therapy in patients with advanced-stage MF or SS (ClinicalTrials.gov Identifier: NCT02953301). Another promising treatment modality includes low-dose total skin electron beam treatment followed by mechlorethamine<sup><a href="#ref-84">84</a></sup>, which is being investigated in a phase 2 trial (ClinicalTrials.gov Identifier: NCT02881749). A phase 3 trial on lenalidomide maintenance in advanced CTCL was terminated early following withdrawal of funding support and thus was underpowered for analysis<sup><a href="#ref-85">85</a></sup>.</p><p class="" id=d1044e747>Immune checkpoint inhibitors have revolutionized treatment of many cancer types, and there have been durable responses in some patients even after cessation of therapy<sup><a href="#ref-86">86</a></sup>. As briefly mentioned above, these new agents might also be an option for CTCL<sup><a href="#ref-87">87</a></sup>. In a phase II trial of patients with advanced, heavily pre-treated MF and SS, the PD-1 inhibitor pembrolizumab demonstrated significant anti-tumor activity and had overall response rates of 38% and a favorable safety profile<sup><a href="#ref-88">88</a></sup>. Ongoing treatment responses at last follow-up were observed in one third of patients<sup><a href="#ref-88">88</a></sup>. Besides pembrolizumab, the PD-1 blocker nivolumab and the PD-L1 inhibitors durvalumab and atezolizumab are being investigated in clinical trials. Despite promising initial results, caution needs to be exerted as PD-1 blockade might also accelerate growth of T-cell malignancies, as seen in adult T-cell leukemia/lymphoma that showed explosive progression of disease in the first three patients<sup><a href="#ref-89">89</a></sup>.</p><p class="" id=d1044e770>Other treatment approaches being evaluated in early clinical trials include the SYK/JAK inhibitor cerdulatinib, an anti-KIR antibody (IPH4102), the microRNA Mir-155 inhibitor cobomarsen, and the CD70 blocker cusatuzumab<sup><a href="#ref-82">82</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d1044e781>Outlook</h2><p class="" id=d1044e784>Our understanding of the pathogenesis of CTCL has steadily increased within the last few years, but many aspects are still only insufficiently understood, necessitating further basic and translational research approaches. Whereas many patients show an indolent and self-limiting course, some patients progress. For those patients, treatment options are often limited and can harbor significant toxicity. In line with this, early-stage disease should preferentially be treated with skin-directed therapies and, in case of relapse and after initial therapeutic success, should be used in a repetitive manner. Systemic treatment should preferably be kept for advanced-stage disease or patients with refractory cutaneous involvement (for example, after secondary loss of efficacy with skin-directed therapies). Generally, the management of patients with CTCL should be reserved for specialized centers, which also offer the advantage of access to multicenter clinical trials. It is noteworthy that HRQoL is of significant importance in CTCL, profoundly influencing patients’ quality of life in terms of a visible stigma and its potential lethality<sup><a href="#ref-90">90</a></sup>. Accordingly, HRQoL and its maintenance in MF/SS are of utmost importance in the face of current palliative treatment approaches in the majority of cases.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d1044e795 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d1625>References</h2><div class="section ref-list"><a name=d1044e795 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d1044e802 class=n-a></a>Trautinger F, Knobler R, Willemze R, <i> et al.</i>: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. <i>Eur J Cancer.</i> 2006; <b>42</b>(8): 1014–30. <a target=xrefwindow id=d1044e813 href="http://www.ncbi.nlm.nih.gov/pubmed/16574401">PubMed Abstract </a> | <a target=xrefwindow id=d1044e816 href="https://doi.org/10.1016/j.ejca.2006.01.025">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d1044e825 class=n-a></a>Trautinger F, Eder J, Assaf C, <i> et al.</i>: European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. <i>Eur J Cancer.</i> 2017; <b>77</b>: 57–74. <a target=xrefwindow id=d1044e836 href="http://www.ncbi.nlm.nih.gov/pubmed/28365528">PubMed Abstract </a> | <a target=xrefwindow id=d1044e839 href="https://doi.org/10.1016/j.ejca.2017.02.027">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d1044e848 class=n-a></a>Willemze R, Cerroni L, Kempf W, <i> et al.</i>: The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. <i>Blood.</i> 2019; <b>133</b>(16): 1703–14. <a target=xrefwindow id=d1044e859 href="http://www.ncbi.nlm.nih.gov/pubmed/30635287">PubMed Abstract </a> | <a target=xrefwindow id=d1044e862 href="https://doi.org/10.1182/blood-2018-11-881268">Publisher Full Text </a> | <a target=xrefwindow id=d1044e866 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6473500">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d1044e875 class=n-a></a>Kim YH, Jensen RA, Watanabe GL, <i> et al.</i>: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. <i>Arch Dermatol.</i> 1996; <b>132</b>(11): 1309. <a target=xrefwindow id=d1044e886 href="http://www.ncbi.nlm.nih.gov/pubmed/8915308">PubMed Abstract </a> | <a target=xrefwindow id=d1044e889 href="https://doi.org/10.1001/archderm.1996.03890350051009">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d1044e898 class=n-a></a>Porkert S, Lehner-Baumgartner E, Valencak J, <i> et al.</i>: Patients' Illness Perception as a Tool to Improve Individual Disease Management in Primary Cutaneous Lymphomas. <i>Acta Derm Venereol.</i> 2018; <b>98</b>(2): 240–5. <a target=xrefwindow id=d1044e909 href="http://www.ncbi.nlm.nih.gov/pubmed/29048099">PubMed Abstract </a> | <a target=xrefwindow id=d1044e912 href="https://doi.org/10.2340/00015555-2819">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d1044e922 class=n-a></a>Molloy K, Jonak C, Woei-A-Jin FJSH, <i> et al.</i>: Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. <i>Br J Dermatol.</i> 2019; <b>182</b>(3): 770–9. <a target=xrefwindow id=d1044e933 href="http://www.ncbi.nlm.nih.gov/pubmed/31049926">PubMed Abstract </a> | <a target=xrefwindow id=d1044e936 href="https://doi.org/10.1111/bjd.18089">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d1044e945 class=n-a></a>Scarisbrick JJ, Quaglino P, Prince HM, <i> et al.</i>: The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>Br J Dermatol.</i> 2019; <b>181</b>(2): 350–7. <a target=xrefwindow id=d1044e956 href="http://www.ncbi.nlm.nih.gov/pubmed/30267549">PubMed Abstract </a> | <a target=xrefwindow id=d1044e959 href="https://doi.org/10.1111/bjd.17258">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1097458"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e968 class=n-a></a>Willemze R, Jaffe ES, Burg G, <i> et al.</i>: WHO-EORTC classification for cutaneous lymphomas. <i>Blood.</i> 2005; <b>105</b>(10): 3768–85. <a target=xrefwindow id=d1044e979 href="http://www.ncbi.nlm.nih.gov/pubmed/15692063">PubMed Abstract </a> | <a target=xrefwindow id=d1044e982 href="https://doi.org/10.1182/blood-2004-09-3502">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1097458">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d1044e995 class=n-a></a>Arulogun SO, Prince HM, Ng J, <i> et al.</i>: Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. <i>Blood.</i> 2008; <b>112</b>(8): 3082–7. <a target=xrefwindow id=d1044e1006 href="http://www.ncbi.nlm.nih.gov/pubmed/18647960">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1009 href="https://doi.org/10.1182/blood-2008-05-154609">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d1044e1018 class=n-a></a>Agar NS, Wedgeworth E, Crichton S, <i> et al.</i>: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: Validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. <i>J Clin Oncol.</i> 2010; <b>28</b>(31): 4730–9. <a target=xrefwindow id=d1044e1029 href="http://www.ncbi.nlm.nih.gov/pubmed/20855822">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1032 href="https://doi.org/10.1200/JCO.2009.27.7665">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d1044e1041 class=n-a></a>Wilcox RA: Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. <i>Am J Hematol.</i> 2017; <b>92</b>(10): 1085–102. <a target=xrefwindow id=d1044e1049 href="http://www.ncbi.nlm.nih.gov/pubmed/28872191">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1052 href="https://doi.org/10.1002/ajh.24876">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d1044e1062 class=n-a></a>Litvinov IV, Tetzlaff MT, Thibault P, <i> et al.</i>: Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. <i>Oncoimmunology.</i> 2017; <b>6</b>(5): e1306618. <a target=xrefwindow id=d1044e1073 href="http://www.ncbi.nlm.nih.gov/pubmed/28638728">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1076 href="https://doi.org/10.1080/2162402X.2017.1306618">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1080 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5468001">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d1044e1089 class=n-a></a>Damsky WE, Choi J: Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. <i>Curr Treat Options Oncol.</i> 2016; <b>17</b>(7): 33. <a target=xrefwindow id=d1044e1097 href="http://www.ncbi.nlm.nih.gov/pubmed/27262707">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1100 href="https://doi.org/10.1007/s11864-016-0410-8">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d1044e1109 class=n-a></a>Dereure O, Levi E, Kadin ME, <i> et al.</i>: Infrequent Fas Mutations but No Bax or p53 Mutations in Early Mycosis Fungoides: A Possible Mechanism for the Accumulation of Malignant T Lymphocytes in the Skin. <i>J Invest Dermatol.</i> 2002; <b>118</b>(6): 949–56. <a target=xrefwindow id=d1044e1120 href="http://www.ncbi.nlm.nih.gov/pubmed/12060388">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1123 href="https://doi.org/10.1046/j.1523-1747.2002.01794.x">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d1044e1132 class=n-a></a>Wang L, Ni X, Covington KR, <i> et al.</i>: Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. <i>Nat Genet.</i> 2015; <b>47</b>(12): 1426–34. <a target=xrefwindow id=d1044e1143 href="http://www.ncbi.nlm.nih.gov/pubmed/26551670">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1146 href="https://doi.org/10.1038/ng.3444">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1150 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4829974">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725708573"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1159 class=n-a></a>Ungewickell A, Bhaduri A, Rios E, <i> et al.</i>: Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. <i>Nat Genet.</i> 2015; <b>47</b>(9): 1056–60. <a target=xrefwindow id=d1044e1170 href="http://www.ncbi.nlm.nih.gov/pubmed/26258847">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1173 href="https://doi.org/10.1038/ng.3370">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1177 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6091217">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725708573">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d1044e1190 class=n-a></a>Sandoval J, Díaz-Lagares A, Salgado R, <i> et al.</i>: MicroRNA Expression Profiling and DNA Methylation Signature for Deregulated MicroRNA in Cutaneous T-Cell Lymphoma. <i>J Invest Dermatol.</i> 2015; <b>135</b>(4): 1128–37. <a target=xrefwindow id=d1044e1201 href="http://www.ncbi.nlm.nih.gov/pubmed/25405321">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1204 href="https://doi.org/10.1038/jid.2014.487">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d1044e1214 class=n-a></a>McGirt LY, Jia P, Baerenwald DA, <i> et al.</i>: Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. <i>Blood.</i> 2015; <b>126</b>(4): 508–19. <a target=xrefwindow id=d1044e1225 href="http://www.ncbi.nlm.nih.gov/pubmed/26082451">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1228 href="https://doi.org/10.1182/blood-2014-11-611194">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1232 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4513251">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d1044e1241 class=n-a></a>da Silva Almeida AC, Abate F, Khiabanian H, <i> et al.</i>: The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. <i>Nat Genet.</i> 2015; <b>47</b>(12): 1465–70. <a target=xrefwindow id=d1044e1252 href="http://www.ncbi.nlm.nih.gov/pubmed/26551667">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1255 href="https://doi.org/10.1038/ng.3442">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1259 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4878831">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733176068"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1268 class=n-a></a>Mervis JS, McGee JS: Epigenetic therapy and dermatologic disease: Moving beyond CTCL. <i>J Dermatolog Treat.</i> 2018; <b>30</b>(1): 68–73. <a target=xrefwindow id=d1044e1276 href="http://www.ncbi.nlm.nih.gov/pubmed/29726727">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1279 href="https://doi.org/10.1080/09546634.2018.1473550">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733176068">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d1044e1292 class=n-a></a>Campbell JJ, Clark RA, Watanabe R, <i> et al.</i>: Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: A biologic rationale for their distinct clinical behaviors. <i>Blood.</i> 2010; <b>116</b>(5): 767–71. <a target=xrefwindow id=d1044e1303 href="http://www.ncbi.nlm.nih.gov/pubmed/20484084">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1306 href="https://doi.org/10.1182/blood-2009-11-251926">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1310 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2918332">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d1044e1319 class=n-a></a>Clark RA, Watanabe R, Teague JE, <i> et al.</i>: Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients. <i>Sci Transl Med.</i> 2012; <b>4</b>(117): 117ra7. <a target=xrefwindow id=d1044e1330 href="http://www.ncbi.nlm.nih.gov/pubmed/22261031">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1333 href="https://doi.org/10.1126/scitranslmed.3003008">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1337 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3373186">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d1044e1346 class=n-a></a>Krejsgaard T, Ralfkiaer U, Clasen-Linde E, <i> et al.</i>: Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. <i>J Invest Dermatol.</i> 2011; <b>131</b>(6): 1331–8. <a target=xrefwindow id=d1044e1357 href="http://www.ncbi.nlm.nih.gov/pubmed/21346774">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1360 href="https://doi.org/10.1038/jid.2011.27">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d1044e1370 class=n-a></a>Berger CL, Tigelaar R, Cohen J, <i> et al.</i>: Cutaneous T-cell lymphoma: Malignant proliferation of T-regulatory cells. <i>Blood.</i> 2005; <b>105</b>(4): 1640–7. <a target=xrefwindow id=d1044e1381 href="http://www.ncbi.nlm.nih.gov/pubmed/15514008">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1384 href="https://doi.org/10.1182/blood-2004-06-2181">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d1044e1393 class=n-a></a>Geskin LJ, Viragova S, Stolz DB, <i> et al.</i>: Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. <i>Blood.</i> 2015; <b>125</b>(18): 2798–805. <a target=xrefwindow id=d1044e1404 href="http://www.ncbi.nlm.nih.gov/pubmed/25628470">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1407 href="https://doi.org/10.1182/blood-2014-07-590398">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1411 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4424628">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733477717"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1420 class=n-a></a>Fujii K: New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma. <i>Front Oncol.</i> 2018; <b>8</b>: 198. <a target=xrefwindow id=d1044e1428 href="http://www.ncbi.nlm.nih.gov/pubmed/29915722">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1431 href="https://doi.org/10.3389/fonc.2018.00198">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1434 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5994426">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733477717">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d1044e1447 class=n-a></a>Gjerdrum LM, Woetmann A, Odum N, <i> et al.</i>: FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: Association with disease stage and survival. <i>Leukemia.</i> 2007; <b>21</b>(12): 2512–8. <a target=xrefwindow id=d1044e1458 href="http://www.ncbi.nlm.nih.gov/pubmed/17713545">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1461 href="https://doi.org/10.1038/sj.leu.2404913">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725670051"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1470 class=n-a></a>Wherry EJ, Kurachi M: Molecular and cellular insights into T cell exhaustion. <i>Nat Rev Immunol.</i> 2015; <b>15</b>(8): 486–99. <a target=xrefwindow id=d1044e1478 href="http://www.ncbi.nlm.nih.gov/pubmed/26205583">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1481 href="https://doi.org/10.1038/nri3862">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1484 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4889009">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725670051">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d1044e1497 class=n-a></a>Vowels BR, Lessin SR, Cassin M, <i> et al.</i>: Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. <i>J Invest Dermatol.</i> 1994; <b>103</b>(5): 669–73. <a target=xrefwindow id=d1044e1508 href="http://www.ncbi.nlm.nih.gov/pubmed/7963654">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1511 href="https://doi.org/10.1111/1523-1747.ep12398454">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736561170"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1521 class=n-a></a>Vieyra-Garcia P, Crouch JD, O'Malley JT, <i> et al.</i>: Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. <i>JCI Insight.</i> 2019; <b>4</b>(1): pii: 124233. <a target=xrefwindow id=d1044e1532 href="http://www.ncbi.nlm.nih.gov/pubmed/30626755">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1535 href="https://doi.org/10.1172/jci.insight.124233">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1539 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6485670">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736561170">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d1044e1552 class=n-a></a>Guenova E, Watanabe R, Teague JE, <i> et al.</i>: TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. <i>Clin Cancer Res.</i> 2013; <b>19</b>(14): 3755–63. <a target=xrefwindow id=d1044e1563 href="http://www.ncbi.nlm.nih.gov/pubmed/23785046">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1566 href="https://doi.org/10.1158/1078-0432.CCR-12-3488">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1570 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3715586">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d1044e1579 class=n-a></a>Thumann P, Lüftl M, Moc I, <i> et al.</i>: Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: Implications for dendritic cell-based immunotherapy. <i>Br J Dermatol.</i> 2003; <b>149</b>(6): 1128–42. <a target=xrefwindow id=d1044e1590 href="http://www.ncbi.nlm.nih.gov/pubmed/14674889">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1593 href="https://doi.org/10.1111/j.1365-2133.2003.05674.x">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d1044e1602 class=n-a></a>Talpur R, Singh L, Daulat S, <i> et al.</i>: Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sezary Syndrome from 1982 to 2009. <i>Clin Cancer Res.</i> 2012; <b>18</b>(18): 5051–60. <a target=xrefwindow id=d1044e1613 href="http://www.ncbi.nlm.nih.gov/pubmed/22850569">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1616 href="https://doi.org/10.1158/1078-0432.CCR-12-0604">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1620 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3857608">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d1044e1629 class=n-a></a>Talpur R, Bassett R, Duvic M: Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. <i>Br J Dermatol.</i> 2008; <b>159</b>(1): 105–12. <a target=xrefwindow id=d1044e1637 href="http://www.ncbi.nlm.nih.gov/pubmed/18489588">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1640 href="https://doi.org/10.1111/j.1365-2133.2008.08612.x">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736806234"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1649 class=n-a></a>Blümel E, Willerslev-Olsen A, Gluud M, <i> et al.</i>: Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma. <i>Oncoimmunology.</i> 2019; <b>8</b>(11): e1641387. <a target=xrefwindow id=d1044e1660 href="http://www.ncbi.nlm.nih.gov/pubmed/31646088">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1663 href="https://doi.org/10.1080/2162402X.2019.1641387">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1667 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6791457">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736806234">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d1044e1681 class=n-a></a>Dummer R, Eichmüller S, Gellrich S, <i> et al.</i>: Phase II Clinical Trial of Intratumoral Application of TG1042 (Adenovirus-interferon-γ) in Patients With Advanced Cutaneous T-cell Lymphomas and Multilesional Cutaneous B-cell Lymphomas. <i>Mol Ther.</i> 2010; <b>18</b>(6): 1244–7. <a target=xrefwindow id=d1044e1692 href="http://www.ncbi.nlm.nih.gov/pubmed/20372104">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1695 href="https://doi.org/10.1038/mt.2010.52">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1699 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2889748">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d1044e1708 class=n-a></a>Miyagaki T, Sugaya M, Fujita H, <i> et al.</i>: Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. <i>J Invest Dermatol.</i> 2010; <b>130</b>(9): 2304–11. <a target=xrefwindow id=d1044e1719 href="http://www.ncbi.nlm.nih.gov/pubmed/20505746">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1722 href="https://doi.org/10.1038/jid.2010.128">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d1044e1731 class=n-a></a>Banchereau J, Steinman RM: Dendritic cells and the control of immunity. <i>Nature.</i> 1998; <b>392</b>(6673): 245–52. <a target=xrefwindow id=d1044e1739 href="http://www.ncbi.nlm.nih.gov/pubmed/9521319">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1742 href="https://doi.org/10.1038/32588">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d1044e1751 class=n-a></a>Lüftl M, Feng A, Licha E, <i> et al.</i>: Dendritic cells and apoptosis in mycosis fungoides. <i>Br J Dermatol.</i> 2002; <b>147</b>(6): 1171–9. <a target=xrefwindow id=d1044e1762 href="http://www.ncbi.nlm.nih.gov/pubmed/12452867">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1765 href="https://doi.org/10.1046/j.1365-2133.2002.04994.x">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d1044e1774 class=n-a></a>Schlapbach C, Ochsenbein A, Kaelin U, <i> et al.</i>: High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. <i>J Am Acad Dermatol.</i> 2010; <b>62</b>(6): 995–1004. <a target=xrefwindow id=d1044e1785 href="http://www.ncbi.nlm.nih.gov/pubmed/20466174">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1788 href="https://doi.org/10.1016/j.jaad.2009.06.082">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720025740"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1797 class=n-a></a>Rabenhorst A, Schlaak M, Heukamp LC, <i> et al.</i>: Mast cells play a protumorigenic role in primary cutaneous lymphoma. <i>Blood.</i> 2012; <b>120</b>(10): 2042–54. <a target=xrefwindow id=d1044e1808 href="http://www.ncbi.nlm.nih.gov/pubmed/22837530">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1811 href="https://doi.org/10.1182/blood-2012-03-415638">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720025740">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d1044e1825 class=n-a></a>Pileri A, Agostinelli C, Sessa M, <i> et al.</i>: Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. <i>Virchows Arch.</i> 2017; <b>470</b>(5): 575–82. <a target=xrefwindow id=d1044e1836 href="http://www.ncbi.nlm.nih.gov/pubmed/28321511">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1839 href="https://doi.org/10.1007/s00428-017-2107-1">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733396332"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1848 class=n-a></a>Pham LV, Pogue E, Ford RJ: The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas. <i>Front Oncol.</i> 2018; <b>8</b>: 147. <a target=xrefwindow id=d1044e1856 href="http://www.ncbi.nlm.nih.gov/pubmed/29868471">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1859 href="https://doi.org/10.3389/fonc.2018.00147">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1862 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5951963">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733396332">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d1044e1875 class=n-a></a>Furudate S, Fujimura T, Kakizaki A, <i> et al.</i>: The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides. <i>Exp Dermatol.</i> 2016; <b>25</b>(2): 107–12. <a target=xrefwindow id=d1044e1886 href="http://www.ncbi.nlm.nih.gov/pubmed/26441016">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1889 href="https://doi.org/10.1111/exd.12873">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d1044e1898 class=n-a></a>Wu X, Schulte BC, Zhou Y, <i> et al.</i>: Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development <i>in vivo</i>. <i>J Invest Dermatol.</i> 2014; <b>134</b>(11): 2814–22. <a target=xrefwindow id=d1044e1912 href="http://www.ncbi.nlm.nih.gov/pubmed/24780929">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1916 href="https://doi.org/10.1038/jid.2014.206">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d1044e1925 class=n-a></a>Sugaya M, Miyagaki T, Ohmatsu H, <i> et al.</i>: Association of the numbers of CD163<sup>+</sup> cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma. <i>J Dermatol Sci.</i> 2012; <b>68</b>(1): 45–51. <a target=xrefwindow id=d1044e1939 href="http://www.ncbi.nlm.nih.gov/pubmed/22884782">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1943 href="https://doi.org/10.1016/j.jdermsci.2012.07.007">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d1044e1952 class=n-a></a>Ralfkiaer U, Hagedorn PH, Bangsgaard N, <i> et al.</i>: Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). <i>Blood.</i> 2011; <b>118</b>(22): 5891–900. <a target=xrefwindow id=d1044e1963 href="http://www.ncbi.nlm.nih.gov/pubmed/21865341">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1966 href="https://doi.org/10.1182/blood-2011-06-358382">Publisher Full Text </a> | <a target=xrefwindow id=d1044e1970 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3342856">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11652958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e1980 class=n-a></a>Jokinen CH, Fromm JR, Argenyi ZB, <i> et al.</i>: Flow cytometric evaluation of skin biopsies for mycosis fungoides. <i>Am J Dermatopathol.</i> 2011; <b>33</b>(5): 483–91. <a target=xrefwindow id=d1044e1991 href="http://www.ncbi.nlm.nih.gov/pubmed/21552102">PubMed Abstract </a> | <a target=xrefwindow id=d1044e1994 href="https://doi.org/10.1097/DAD.0b013e31820595da">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11652958">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d1044e2007 class=n-a></a>Ponti R, Quaglino P, Novelli M, <i> et al.</i>: T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: Correlation with clinical, histological and immunophenotypical findings. <i>Br J Dermatol.</i> 2005; <b>153</b>(3): 565–73. <a target=xrefwindow id=d1044e2018 href="http://www.ncbi.nlm.nih.gov/pubmed/16120144">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2021 href="https://doi.org/10.1111/j.1365-2133.2005.06649.x">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733876169"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2030 class=n-a></a>Rea B, Haun P, Emerson R, <i> et al.</i>: Role of high-throughput sequencing in the diagnosis of cutaneous T-cell lymphoma. <i>J Clin Pathol.</i> 2018; <b>71</b>(9): 814–20. <a target=xrefwindow id=d1044e2041 href="http://www.ncbi.nlm.nih.gov/pubmed/29636372">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2044 href="https://doi.org/10.1136/jclinpath-2018-205004">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733876169">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d1044e2057 class=n-a></a>Zhang Y, Wang Y, Yu R, <i> et al.</i>: Molecular markers of early-stage mycosis fungoides. <i>J Invest Dermatol.</i> 2012; <b>132</b>(6): 1698–706. <a target=xrefwindow id=d1044e2068 href="http://www.ncbi.nlm.nih.gov/pubmed/22377759">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2071 href="https://doi.org/10.1038/jid.2012.13">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d1044e2080 class=n-a></a>Schrader AM, Jansen PM, Willemze R: TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4<sup>+</sup> CD8<sup>-</sup> phenotype. <i>Br J Dermatol.</i> 2016; <b>175</b>(2): 382–6. <a target=xrefwindow id=d1044e2094 href="http://www.ncbi.nlm.nih.gov/pubmed/26931394">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2098 href="https://doi.org/10.1111/bjd.14508">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d1044e2107 class=n-a></a>Fierro MT, Novelli M, Quaglino P, <i> et al.</i>: Heterogeneity of circulating CD4+ memory T-cell subsets in erythrodermic patients: CD27 analysis can help to distinguish cutaneous T-cell lymphomas from inflammatory erythroderma. <i>Dermatology.</i> 2008; <b>216</b>(3): 213–21. <a target=xrefwindow id=d1044e2118 href="http://www.ncbi.nlm.nih.gov/pubmed/18182812">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2121 href="https://doi.org/10.1159/000112928">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d1044e2131 class=n-a></a>Lefrançois P, Xie P, Wang L, <i> et al.</i>: Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. <i>Oncoimmunology.</i> 2018; <b>7</b>(8): e1467856. <a target=xrefwindow id=d1044e2142 href="http://www.ncbi.nlm.nih.gov/pubmed/30221071">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2145 href="https://doi.org/10.1080/2162402X.2018.1467856">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2149 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6136868">Free Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733198100"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2158 class=n-a></a>de Masson A, O’Malley JT, Elco CP, <i> et al.</i>: High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. <i>Sci Transl Med.</i> 2018; <b>10</b>(440): eaar5894. <a target=xrefwindow id=d1044e2169 href="http://www.ncbi.nlm.nih.gov/pubmed/29743350">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2172 href="https://doi.org/10.1126/scitranslmed.aar5894">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6366329">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733198100">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d1044e2190 class=n-a></a>Sanz-Bueno J, Lora D, Monsálvez V, <i> et al.</i>: The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. <i>Br J Dermatol.</i> 2016; <b>175</b>(4): 794–6. <a target=xrefwindow id=d1044e2201 href="http://www.ncbi.nlm.nih.gov/pubmed/26990536">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2204 href="https://doi.org/10.1111/bjd.14559">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d1044e2213 class=n-a></a>Daggett RN, Kurata M, Abe S, <i> et al.</i>: Expression dynamics of CXCL 12 and CXCR 4 during the progression of mycosis fungoides. <i>Br J Dermatol.</i> 2014; <b>171</b>(4): 722–31. <a target=xrefwindow id=d1044e2224 href="http://www.ncbi.nlm.nih.gov/pubmed/24725174">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2227 href="https://doi.org/10.1111/bjd.13054">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d1044e2236 class=n-a></a>Maj J, Jankowska-Konsur AM, Hałoń A, <i> et al.</i>: Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides. <i>Postepy Dermatol Alergol.</i> 2015; <b>32</b>(6): 437–42. <a target=xrefwindow id=d1044e2247 href="http://www.ncbi.nlm.nih.gov/pubmed/26755907">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2250 href="https://doi.org/10.5114/pdia.2015.48034">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4697019">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d1044e2263 class=n-a></a>Huang Y, Litvinov IV, Wang Y, <i> et al.</i>: Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis. <i>Oncotarget.</i> 2014; <b>5</b>(12): 4418–25. <a target=xrefwindow id=d1044e2274 href="http://www.ncbi.nlm.nih.gov/pubmed/24947046">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2277 href="https://doi.org/10.18632/oncotarget.2031">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2281 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4147334">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d1044e2291 class=n-a></a>Dulmage BO, Geskin LJ, <i> et al.</i>: Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. <i>Br J Dermatol.</i> 2013; <b>169</b>(6): 1188–97. <a target=xrefwindow id=d1044e2302 href="http://www.ncbi.nlm.nih.gov/pubmed/23937674">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2305 href="https://doi.org/10.1111/bjd.12578">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2309 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3954533">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d1044e2318 class=n-a></a>Hurabielle C, Thonnart N, Ram-Wolff C, <i> et al.</i>: Usefulness of KIR3DL2 to Diagnose, Follow-Up, and Manage the Treatment of Patients with Sézary Syndrome. <i>Clin Cancer Res.</i> 2017; <b>23</b>(14): 3619–27. <a target=xrefwindow id=d1044e2329 href="http://www.ncbi.nlm.nih.gov/pubmed/28119365">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2332 href="https://doi.org/10.1158/1078-0432.CCR-16-3185">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d1044e2341 class=n-a></a>Dulmage B, Geskin L, Guitart J, <i> et al.</i>: The biomarker landscape in mycosis fungoides and Sézary syndrome. <i>Exp Dermatol.</i> 2017; <b>26</b>(8): 668–76. <a target=xrefwindow id=d1044e2352 href="http://www.ncbi.nlm.nih.gov/pubmed/27897325">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2355 href="https://doi.org/10.1111/exd.13261">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2359 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5489366">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735603153"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2368 class=n-a></a>Gaydosik AM, Tabib T, Geskin LJ, <i> et al.</i>: Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors. <i>Clin Cancer Res.</i> 2019; <b>25</b>(14): 4443–54. <a target=xrefwindow id=d1044e2379 href="http://www.ncbi.nlm.nih.gov/pubmed/31010835">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2382 href="https://doi.org/10.1158/1078-0432.CCR-19-0148">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2386 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6635080">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735603153">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d1044e2400 class=n-a></a>Litvinov IV, Jones DA, Sasseville D, <i> et al.</i>: Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. <i>Clin Cancer Res.</i> 2010; <b>16</b>(7): 2106–14. <a target=xrefwindow id=d1044e2411 href="http://www.ncbi.nlm.nih.gov/pubmed/20233883">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2414 href="https://doi.org/10.1158/1078-0432.CCR-09-2879">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2418 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2853253">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d1044e2427 class=n-a></a>Shin J, Monti S, Aires DJ, <i> et al.</i>: Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. <i>Blood.</i> 2007; <b>110</b>(8): 3015–27. <a target=xrefwindow id=d1044e2438 href="http://www.ncbi.nlm.nih.gov/pubmed/17638852">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2441 href="https://doi.org/10.1182/blood-2006-12-061507">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2445 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2018675">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d1044e2455 class=n-a></a>Shen-Orr SS, Gaujoux R: Computational deconvolution: extracting cell type-specific information from heterogeneous samples. <i>Curr Opin Immunol.</i> 2013; <b>25</b>(5): 571–8. <a target=xrefwindow id=d1044e2463 href="http://www.ncbi.nlm.nih.gov/pubmed/24148234">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2466 href="https://doi.org/10.1016/j.coi.2013.09.015">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2469 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3874291">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733655452"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2478 class=n-a></a>Nguyen A, Khoo WH, Moran I, <i> et al.</i>: Single Cell RNA Sequencing of Rare Immune Cell Populations. <i>Front Immunol.</i> 2018; <b>9</b>: 1553. <a target=xrefwindow id=d1044e2489 href="http://www.ncbi.nlm.nih.gov/pubmed/30022984">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2492 href="https://doi.org/10.3389/fimmu.2018.01553">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2496 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6039576">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733655452">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735011901"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2510 class=n-a></a>Borcherding N, Voigt AP, Liu V, <i> et al.</i>: Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. <i>Clin Cancer Res.</i> 2019; <b>25</b>(10): 2996–3005. <a target=xrefwindow id=d1044e2521 href="http://www.ncbi.nlm.nih.gov/pubmed/30718356">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2524 href="https://doi.org/10.1158/1078-0432.CCR-18-3309">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2528 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6659117">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735011901">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735839329"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2542 class=n-a></a>Iqbal M, Reljic T, Klocksieben F, <i> et al.</i>: Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1-Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biol Blood Marrow Transplant.</i> 2019; <b>25</b>(8): 1695–700. <a target=xrefwindow id=d1044e2553 href="http://www.ncbi.nlm.nih.gov/pubmed/31132453">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2556 href="https://doi.org/10.1016/j.bbmt.2019.05.027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735839329">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736560086"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2570 class=n-a></a>Sivanand A, Surmanowicz P, Alhusayen R, <i> et al.</i>: Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. <i>J Cutan Med Surg.</i> 2019; <b>23</b>(5): 537–44. <a target=xrefwindow id=d1044e2581 href="http://www.ncbi.nlm.nih.gov/pubmed/31353944">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2584 href="https://doi.org/10.1177/1203475419867610">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736560086">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736389689"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2598 class=n-a></a>Ramelyte E, Dummer R, Guenova E: Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. <i>Expert Opin Investig Drugs.</i> 2019; <b>28</b>(9): 799–809. <a target=xrefwindow id=d1044e2606 href="http://www.ncbi.nlm.nih.gov/pubmed/31398295">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2609 href="https://doi.org/ 10.1080/13543784.2019.1654995">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736389689">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717962333"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2624 class=n-a></a>Lessin SR, Duvic M, Guitart J, <i> et al.</i>: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. <i>JAMA Dermatol.</i> 2013; <b>149</b>(1): 25. <a target=xrefwindow id=d1044e2635 href="http://www.ncbi.nlm.nih.gov/pubmed/23069814">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2638 href="https://doi.org/10.1001/2013.jamadermatol.541">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2642 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3662469">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717962333">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735366905"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2656 class=n-a></a>Vieyra-Garcia P, Fink-Puches R, Porkert S, <i> et al.</i>: Evaluation of Low-Dose, Low-Frequency Oral Psoralen-UV-A Treatment With or Without Maintenance on Early-Stage Mycosis Fungoides: A Randomized Clinical Trial. <i>JAMA Dermatol.</i> 2019; <b>155</b>(5): 538–47. <a target=xrefwindow id=d1044e2667 href="http://www.ncbi.nlm.nih.gov/pubmed/30892603">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2670 href="https://doi.org/10.1001/jamadermatol.2018.5905">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2674 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6506892">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735366905">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d1044e2687 class=n-a></a>Shipman AR, Scarisbrick J: New Treatment Options for Mycosis Fungoides. <i>Indian J Dermatol.</i> 2016; <b>61</b>(1): 119. <a target=xrefwindow id=d1044e2695 href="http://www.ncbi.nlm.nih.gov/pubmed/26955126">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2698 href="https://doi.org/10.4103/0019-5154.174085">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2701 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4763636">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725687268"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2710 class=n-a></a>Rook AH, Gelfand JM, Wysocka M, <i> et al.</i>: Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. <i>Blood.</i> 2015; <b>126</b>(12): 1452–61. <a target=xrefwindow id=d1044e2721 href="http://www.ncbi.nlm.nih.gov/pubmed/26228486">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2724 href="https://doi.org/10.1182/blood-2015-02-630335">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2728 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4573868">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725687268">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718113069"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2742 class=n-a></a>Quéreux G, Brocard A, Saint-Jean M, <i> et al.</i>: Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. <i>J Am Acad Dermatol.</i> 2013; <b>69</b>(6): 890–7. <a target=xrefwindow id=d1044e2753 href="http://www.ncbi.nlm.nih.gov/pubmed/24041738">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2756 href="https://doi.org/10.1016/j.jaad.2013.07.047">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718113069">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d1044e2770 class=n-a></a>Deaver D, Cauthen A, Cohen G, <i> et al.</i>: Excimer laser in the treatment of mycosis fungoides. <i>J Am Acad Dermatol.</i> 2014; <b>70</b>(6): 1058–60. <a target=xrefwindow id=d1044e2781 href="http://www.ncbi.nlm.nih.gov/pubmed/24775402">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2784 href="https://doi.org/10.1016/j.jaad.2014.01.915">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d1044e2794 class=n-a></a>Lundin J, Hagberg H, Repp R, <i> et al.</i>: Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. <i>Blood.</i> 2003; <b>101</b>(11): 4267–72. <a target=xrefwindow id=d1044e2805 href="http://www.ncbi.nlm.nih.gov/pubmed/12543862">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2808 href="https://doi.org/10.1182/blood-2002-09-2802">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733808601"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2817 class=n-a></a>Kim YH, Bagot M, Pinter-Brown L, <i> et al.</i>: Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncol.</i> 2018; <b>19</b>(9): 1192–204. <a target=xrefwindow id=d1044e2828 href="http://www.ncbi.nlm.nih.gov/pubmed/30100375">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2831 href="https://doi.org/10.1016/S1470-2045(18)30379-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733808601">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1089765"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2845 class=n-a></a>Olsen EA, Kim YH, Kuzel TM, <i> et al.</i>: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. <i>J Clin Oncol.</i> 2007; <b>25</b>(21): 3109–15. <a target=xrefwindow id=d1044e2856 href="http://www.ncbi.nlm.nih.gov/pubmed/17577020">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2859 href="https://doi.org/10.1200/JCO.2006.10.2434">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1089765">F1000 Recommendation</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d1044e2873 class=n-a></a>Duvic M, Talpur R, Ni X, <i> et al.</i>: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). <i>Blood.</i> 2006; <b>109</b>(1): 31–9. <a target=xrefwindow id=d1044e2884 href="http://www.ncbi.nlm.nih.gov/pubmed/16960145">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2887 href="https://doi.org/10.1182/blood-2006-06-025999">Publisher Full Text </a> | <a target=xrefwindow id=d1044e2891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1785068">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d1044e2900 class=n-a></a>Geskin LJ: Highlights in cutaneous T-cell lymphoma from the 60th American Society of Hematology Annual Meeting: A dermatologist's perspective. <i>Clin Adv Hematol Oncol.</i> 2019; <b>17</b>(Suppl 3(2)): 21–3. <a target=xrefwindow id=d1044e2908 href="http://www.ncbi.nlm.nih.gov/pubmed/31545306">PubMed Abstract </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d1044e2917 class=n-a></a>Prince HM, Kim YH, Horwitz SM, <i> et al.</i>: Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet.</i> 2017; <b>390</b>(10094): 555–66. <a target=xrefwindow id=d1044e2928 href="http://www.ncbi.nlm.nih.gov/pubmed/28600132">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2931 href="https://doi.org/10.1016/S0140-6736(17)31266-7">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737829327"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2941 class=n-a></a>Jennings T, Duffy R, Gochoco A, <i> et al.</i>: Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. <i>Chin Clin Oncol.</i> 2019; <b>8</b>(1): 13. <a target=xrefwindow id=d1044e2952 href="http://www.ncbi.nlm.nih.gov/pubmed/30525753">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2955 href="https://doi.org/10.21037/cco.2018.10.01">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737829327">F1000 Recommendation</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d1044e2969 class=n-a></a>Bagot M, Hasan B, Whittaker S, <i> et al.</i>: A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. <i>Eur J Dermatol.</i> 2017; <b>27</b>(3): 286–94. <a target=xrefwindow id=d1044e2980 href="http://www.ncbi.nlm.nih.gov/pubmed/28468739">PubMed Abstract </a> | <a target=xrefwindow id=d1044e2983 href="https://doi.org/10.1684/ejd.2017.3008">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732374119"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e2992 class=n-a></a>Robert C, Ribas A, Hamid O, <i> et al.</i>: Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>J Clin Oncol.</i> 2018; <b>36</b>(17): 1668–74. <a target=xrefwindow id=d1044e3003 href="http://www.ncbi.nlm.nih.gov/pubmed/29283791">PubMed Abstract </a> | <a target=xrefwindow id=d1044e3006 href="https://doi.org/10.1200/JCO.2017.75.6270">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732374119">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/737204205"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e3020 class=n-a></a>Wu X, Singh R, Hsu DK, <i> et al.</i>: A Small Molecule CCR2 Antagonist Depletes Tumor Macrophages and Synergizes with Anti-PD-1 in a Murine Model of Cutaneous T-Cell Lymphoma (CTCL). <i>J Invest Dermatol.</i> 2020. S0022-202X(19)33562-6. <a target=xrefwindow id=d1044e3028 href="http://www.ncbi.nlm.nih.gov/pubmed/31945344">PubMed Abstract </a> | <a target=xrefwindow id=d1044e3031 href="https://doi.org/10.1016/j.jid.2019.11.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/737204205">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/736628042"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e3045 class=n-a></a>Khodadoust MS, Rook AH, Porcu P, <i> et al.</i>: Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. <i>J Clin Oncol.</i> 2020; <b>38</b>(1): 20–8. <a target=xrefwindow id=d1044e3056 href="http://www.ncbi.nlm.nih.gov/pubmed/31532724">PubMed Abstract </a> | <a target=xrefwindow id=d1044e3059 href="https://doi.org/10.1200/JCO.19.01056">Publisher Full Text </a> | <a target=xrefwindow id=d1044e3063 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6943974">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/736628042">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733243036"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d1044e3077 class=n-a></a>Ratner L, Waldmann TA, Janakiram M, <i> et al.</i>: Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. <i>N Engl J Med.</i> 2018; <b>378</b>(20): 1947–8. <a target=xrefwindow id=d1044e3088 href="http://www.ncbi.nlm.nih.gov/pubmed/29768155">PubMed Abstract </a> | <a target=xrefwindow id=d1044e3091 href="https://doi.org/10.1056/NEJMc1803181">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733243036">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d1044e3105 class=n-a></a>Jonak C, Porkert S, Oerlemans S, <i> et al.</i>: Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future. <i>Acta Derm Venereol.</i> 2019; <b>99</b>(7): 640–6. <a target=xrefwindow id=d1044e3116 href="http://www.ncbi.nlm.nih.gov/pubmed/30868169">PubMed Abstract </a> | <a target=xrefwindow id=d1044e3119 href="https://doi.org/10.2340/00015555-3171">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 05 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-331&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-331&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Dermatology, Medical University of Vienna, W&auml;hringer G&uuml;rtel 18-20, Vienna, 1090, Austria<br/> <p> <div class=margin-bottom> Patrick M. Brunner <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Constanze Jonak <br/> <span>Roles: </span> Data Curation, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Robert Knobler <br/> <span>Roles: </span> Conceptualization, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-331/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 05 May 2020, 9:331 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.21922.1">https://doi.org/10.12688/f1000research.21922.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Brunner PM <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24172 data-id=21922 data-downloads="" data-views="" data-scholar="10.12688/f1000research.21922.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-331/v1/pdf?article_uuid=e6ec8946-a656-4e78-9c94-15b791da32af" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.21922.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Brunner PM, Jonak C and Knobler R. Recent advances in understanding and managing cutaneous T-cell lymphomas [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(F1000 Faculty Rev):331 (<a href="https://doi.org/10.12688/f1000research.21922.1" target=_blank>https://doi.org/10.12688/f1000research.21922.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=21922 id=mobile-track-article-signin-21922 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/21922?target=/articles/9-331"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24172 /> <input name=articleId type=hidden value=21922 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Vincent Liu</strong>, Department of Dermatology, University of Iowa Hospitals & Clinics, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Samuel T Hwang</strong>, Department of Dermatology, University of California Davis, School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 05 May 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-331&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-331&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=67016-62929></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=67015-62930></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-331/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>05 May 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Vincent Liu</strong>, Department of Dermatology, University of Iowa Hospitals & Clinics, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Samuel T Hwang</strong>, Department of Dermatology, University of California Davis, School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-331&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-331/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and managing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-331/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-331/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-331/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Brunner PM et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-331/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-331",
            templates : {
                twitter : "Recent advances in understanding and managing cutaneous T-cell.... Brunner PM et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-331/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and managing cutaneous T-cell lymphomas", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and managing cutaneous T-cell lymphomas", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/21922/24172")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24172");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "62929": 1,
                           "62930": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "fa152c6c-9a32-4f2a-ada1-74a14d27d2c0";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-331.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-331.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-331.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-331.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-331.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>